Investor Relations


BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. 

The Company’s commercial product, IGALMI™ (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The safety and effectiveness of IGALMI has not been established beyond 24 hours from the first dose.

BXCL501 is being evaluated for at-home use for the acute treatment of agitation in bipolar and schizophrenia patients, for the acute treatment of agitation associated with Alzheimer’s disease, and as an adjunctive treatment for major depressive disorder. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia.

Under its subsidiary OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immunity activator for the potential treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.



Latest Annual Filing

Form Filing date Description View

Annual report which provides a comprehensive overview of the company for the past year

View HTML EX-101.INS - EX-101.INS
      Sign Up for Email Alerts
Receive updates straight into your inbox

BioXcel Therapeutics, Inc.

Data Provided by Refinitiv.

52 Week High
52 Week Low



BioXcel Therapeutics
Erik Kopp

Investor Relations

BioXcel Therapeutics
Brennan Doyle


FTI Consulting
Helen O'Gorman
T: 718-408-0800